



DATROWAY® may be right for you if you are an adult who has HR+/HER2- breast cancer that cannot be removed by surgery (unresectable) or has spread to other parts of the body (metastatic), and have received prior endocrine-based therapy and chemotherapy for unresectable or metastatic disease.

# EMBRACE YOUR SPARK

HR=hormone receptor; HER2=human epidermal growth factor receptor 2.

Not an actual patient.

## INDICATION AND IMPORTANT SAFETY INFORMATION

### What is DATROWAY®?

DATROWAY is a prescription medicine used to treat adults who have:

- hormone receptor (HR)-positive and human epidermal growth factor receptor 2 (HER2)-negative breast cancer:
  - that cannot be removed by surgery (unresectable) or has spread to other parts of the body (metastatic), **and**
  - who have received prior endocrine-based therapy and chemotherapy treatment for unresectable or metastatic disease.

It is not known if DATROWAY is safe and effective in children.

### What is the most important information I should know about DATROWAY?

#### DATROWAY can cause serious side effects, including:

- **Lung problems that may be severe, life-threatening, or that may lead to death.** If you develop lung problems, your healthcare provider may treat you with corticosteroid medicines. Tell your healthcare provider right away if you get any of the following signs and symptoms:
  - cough
  - trouble breathing or shortness of breath
  - fever
  - other new or worsening breathing symptoms such as chest tightness or wheezing

Please see the complete [Important Safety Information](#) on pages 18-19, the full [Prescribing Information](#), including **WARNINGS AND PRECAUTIONS**, and [Medication Guide](#).

**DATROWAY**<sup>®</sup>  
datopotamab deruxtecan-dlnk  
20 mg/mL INJECTION FOR INTRAVENOUS USE

**WELCOME TO**

**DATROWAY**<sup>®</sup>

datopotamab deruxtecan-dlnk

20 mg/mL INJECTION FOR INTRAVENOUS USE

**A treatment for adults with HR+/HER2– breast cancer that is unresectable\* or metastatic† and who have received prior endocrine-based therapy and chemotherapy for unresectable or metastatic disease.**

**Battling cancer requires courage, resilience, and the right information to help keep you moving forward.**

\*Cannot be removed by surgery.

†Has spread to other parts of the body.

**IMPORTANT SAFETY INFORMATION (CONT'D)**

**What is the most important information I should know about DATROWAY?**

**DATROWAY can cause serious side effects, including:**

- **Eye problems.** Eye problems are common with DATROWAY and can also be severe. Tell your healthcare provider right away if you develop any new or worsening eye problems during treatment with DATROWAY, including dry eyes, eye pain, eye redness, eye swelling, eye irritation, increased tears, feeling like something is in your eyes, discharge from your eyes, eye crusting, sensitivity to light, blurred vision or vision changes.
  - You should use preservative-free lubricating eye drops at least 4 times a day and as needed.
  - Do not wear contact lenses during treatment with DATROWAY unless your eye specialist tells you to.
  - Your healthcare provider will send you to an eye specialist to check your eyes when you start your treatment with DATROWAY, every year during treatment, at the end of treatment, and as needed for any new or worsening signs and symptoms of eye problems.

**Please see the complete Important Safety Information on pages 18-19, the full Prescribing Information, including **WARNINGS AND PRECAUTIONS**, and Medication Guide.**

# Table of contents

As you prepare to start DATROWAY, take a moment to review the information in this brochure with your care team and your care partner. Our goal is to help you feel more informed so you can begin treatment with confidence.

This DATROWAY (pronounced: DAT-roe-way) brochure includes:



## HOW DATROWAY MAY WORK

PAGE 4



## HOW DATROWAY IS GIVEN

PAGE 6



## RESULTS WITH DATROWAY

PAGE 8



## POSSIBLE SIDE EFFECTS

PAGE 12



## MANAGING SELECT SIDE EFFECTS

PAGE 14



## SUPPORT & RESOURCES

PAGE 16

## IMPORTANT SAFETY INFORMATION (CONT'D)

### What is the most important information I should know about DATROWAY? (cont'd)

- **Mouth ulcers and sores.** Mouth ulcers and sores are common with DATROWAY and can also be severe. Tell your healthcare provider right away if you develop mouth pain, swelling, redness, ulcers, or sores during treatment with DATROWAY.
  - Your healthcare provider will prescribe a steroid-containing mouthwash to use 4 times a day and as needed during treatment with DATROWAY.
  - You should hold ice chips or ice water in your mouth during your DATROWAY infusions.

Please see the complete [Important Safety Information](#) on pages 18-19, the full [Prescribing Information](#), including **WARNINGS AND PRECAUTIONS**, and [Medication Guide](#).



Not an actual patient.

**DATROWAY**<sup>®</sup>  
datopotamab deruxtecan-dlnk  
20 mg/mL INJECTION FOR INTRAVENOUS USE



## | HOW DATROWAY MAY WORK

# How DATROWAY is thought to work

DATROWAY is designed to release medicine at the right place, inside the cancer cell.



DATROWAY is designed to identify cancer cells that have Trop-2 (pronounced: trohp-too), a protein found on the surface of cancer cells.

## IMPORTANT SAFETY INFORMATION (CONT'D)

### What is the most important information I should know about DATROWAY? (cont'd)

Your healthcare provider will check you for these side effects during your treatment with DATROWAY. Your healthcare provider may reduce your dose, delay treatment, or completely stop treatment with DATROWAY if you have severe side effects.

- **Harm to your unborn baby.** Tell your healthcare provider right away if you become pregnant or think you might be pregnant during treatment with DATROWAY.
  - If you are able to become pregnant, your healthcare provider should do a pregnancy test before you start treatment with DATROWAY.
  - **Females** who are able to become pregnant should use effective birth control (contraception) during treatment with DATROWAY and for 7 months after the last dose.
  - **Males** who have female partners that are able to become pregnant should use effective birth control (contraception) during treatment with DATROWAY and for 4 months after the last dose.


See “What are the possible side effects of DATROWAY?” for more information about side effects.

Please see the complete [Important Safety Information](#) on pages 18-19, the [full Prescribing Information](#), including **WARNINGS AND PRECAUTIONS**, and [Medication Guide](#).

**DATROWAY**<sup>®</sup>  
datopotamab deruxtecan-dlnk  
20 mg/mL INJECTION FOR INTRAVENOUS USE


# DATROWAY is designed to work in three steps

DATROWAY works by finding cancer cells that have Trop-2 so that it can attack and destroy them. Although DATROWAY is designed to target Trop-2 on cancer cells, it may affect some healthy cells. DATROWAY may not work for everyone.




## IDENTIFY

First, DATROWAY looks for and attaches to Trop-2



## INFILTRATE

It enters the cancer cell



## DESTROY

Lastly, it releases medicine into the cancer cell that helps destroy it. It may also affect other surrounding cells, including healthy ones

Information from laboratory studies suggests that this is how DATROWAY works. The clinical relevance of these features is under investigation.

Trop-2=trophoblast cell-surface antigen 2.

Please see the complete [Important Safety Information](#) on pages 18-19, the [full Prescribing Information](#), including **WARNINGS AND PRECAUTIONS**, and [Medication Guide](#).

**DATROWAY**<sup>®</sup>  
datopotamab deruxtecan-dlnk  
20 mg/mL INJECTION FOR INTRAVENOUS USE

## 3 weeks between doses

Your month might look something like this while on DATROWAY:



- DATROWAY is given through an intravenous (IV) infusion
- You'll receive the IV infusion once every 3 weeks
- It will be given at your treatment center or doctor's office

*Let your care team know if you need anything during your infusion days.*



**If you miss a planned dose of DATROWAY, call your healthcare provider right away to schedule an appointment. Do not wait until the next planned treatment cycle.**

### IMPORTANT SAFETY INFORMATION (CONT'D)

**Before receiving DATROWAY, tell your healthcare provider about all of your medical conditions, including if you:**

- Have lung or breathing problems.
- Have eye problems.
- Use contact lenses.
- Are breastfeeding or plan to breastfeed. It is not known if DATROWAY passes into your breast milk. Do not breastfeed during treatment with DATROWAY and for 1 month after the last dose.

**Tell your healthcare provider about all the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements.**

Please see the complete [Important Safety Information](#) on pages 18-19, the full [Prescribing Information](#), including **WARNINGS AND PRECAUTIONS**, and [Medication Guide](#).

**DATROWAY**<sup>®</sup>  
datopotamab deruxtecan-dlnk  
20 mg/mL INJECTION FOR INTRAVENOUS USE

# What to expect on DATROWAY treatment days



## BEFORE INFUSION

You will be given medicines to help prevent nausea, vomiting, and infusion-related reactions.

**NOTE:** *There are measures you can take at home to help manage certain side effects such as mouth sores or eye problems. See pages 14-15.*



## YOUR FIRST INFUSION

It will take **90 minutes** to complete your first IV infusion. Once the infusion is finished, your care team will monitor you for **at least 1 hour** to see if you have any infusion-related reactions.

**TIP:** *Holding ice chips or ice water in your mouth throughout the infusion may help with mouth sores.*



## FUTURE INFUSIONS

If you did not have any side effects after your first infusion, your infusions could last **30 minutes** each. Just like your first infusion, after your second infusion you will be monitored by your care team for **1 hour** to see if you have any infusion-related reactions. If you did not have any reactions after your second infusion, you will be monitored for **at least 30 minutes** after each following infusion.

**REMEMBER:** *Let your care team know if you're feeling any side effects. Please see pages 12-13 for a select list of possible side effects.*

## IMPORTANT SAFETY INFORMATION (CONT'D)

### How will I receive DATROWAY?

- You will receive DATROWAY into your vein through an intravenous (IV) line by your healthcare provider.
- DATROWAY is usually given 1 time every three weeks (21-day treatment cycle).
- You will receive your first infusion over 90 minutes. If you do not have problems with your first infusion, you may receive your next infusions over 30 minutes.

Please see the complete [Important Safety Information](#) on pages 18-19, the full [Prescribing Information](#), including **WARNINGS AND PRECAUTIONS**, and [Medication Guide](#).

# DATROWAY was studied in a clinical trial

DATROWAY was studied against a chemotherapy treatment.\* The clinical trial included adults who received prior endocrine-based therapy and chemotherapy for HR+/HER2- breast cancer that was unresectable (cannot be removed by surgery) or metastatic (had spread to other parts of the body).



The trial was held at multiple research sites

732  
PEOPLE STUDIED

People were treated with either DATROWAY (365 people) or chemotherapy (367 people)



Patients must have received prior endocrine-based therapy and chemotherapy treatment for unresectable or metastatic disease

28-86  
AGE RANGE

in the clinical trial. Median age was 55

## Important to Note:

- The trial was open-label, meaning that both the people being treated and trial investigators knew which treatments were received. Therefore, the results could have been influenced by people switching to another treatment, leaving the study, or other factors
- People were treated with either DATROWAY or a chemotherapy treatment\*
- At the time of data analysis, people in the trial were monitored for about 11 months after they started treatment. This is called the median duration of follow-up
- Median is the middle number in a set of numbers. It is used to give an accurate picture of a range of data

\*Doctor's choice of chemotherapy (60% of patients received eribulin, 21% of patients received capecitabine, 10% of patients received vinorelbine, and 9% of patients received gemcitabine).

## IMPORTANT SAFETY INFORMATION (CONT'D)

### How will I receive DATROWAY? (cont'd)


- You will be monitored for side effects for at least 1 hour after your first 2 infusions. If you do not have problems after your second infusion, you will be monitored for at least 30 minutes after each following infusion.
- Your healthcare provider will decide how many treatments you need.
- Your healthcare provider will give you medicines before your infusion to help prevent nausea, vomiting, and infusion-related reactions.

Please see the complete [Important Safety Information](#) on pages 18-19, the full [Prescribing Information](#), including **WARNINGS AND PRECAUTIONS**, and [Medication Guide](#).

**DATROWAY**<sup>®</sup>  
datopotamab deruxtecan-dlnk  
20 mg/mL INJECTION FOR INTRAVENOUS USE

# How long people lived on treatment without their cancer growing or spreading

The trial measured median progression-free survival, which is the amount of time that half of the people enrolled in the trial were on treatment before their cancer started growing or spreading.



At the time of evaluation, the median progression-free survival results were considered statistically significant. In a trial, results are considered statistically significant if they are unlikely to have occurred by chance alone, showing that the treatment likely had a real effect.

## Important to Note:

- Please remember that the results you will see are from a clinical trial and each person's experience may differ. Speak with your doctor about what you may expect on DATROWAY treatment

## IMPORTANT SAFETY INFORMATION (CONT'D)

### How will I receive DATROWAY? (cont'd)


- Your healthcare provider may slow down or temporarily stop your infusion of DATROWAY if you have an infusion-related reaction, or permanently stop DATROWAY if you have severe infusion reactions.
- If you miss a planned dose of DATROWAY, call your healthcare provider right away to schedule an appointment. Do not wait until the next planned treatment cycle.

Please see the complete [Important Safety Information](#) on pages 18-19, the full [Prescribing Information](#), including **WARNINGS AND PRECAUTIONS**, and [Medication Guide](#).

**DATROWAY**<sup>®</sup>  
datopotamab deruxtecan-dlnk  
20 mg/mL INJECTION FOR INTRAVENOUS USE

# How long people lived on DATROWAY and chemotherapy

The trial measured median overall survival, which is the amount of time that half of the people in the trial lived since starting treatment.



Overall survival results were not statistically significant. In a trial, results are considered statistically significant if they are unlikely to have occurred by chance. Therefore, these results cannot be fully explained as an effect of the treatment alone.

## IMPORTANT SAFETY INFORMATION (CONT'D)

### What are the possible side effects of DATROWAY?

DATROWAY can cause serious side effects, including:

- See "What is the most important information I should know about DATROWAY?"

The most common side effects of DATROWAY when used in adults with HR-positive HER2-negative breast cancer include:


- |  |   |   |
|--|---|---|
| <ul style="list-style-type: none"> <li>• Nausea</li> <li>• Tiredness</li> <li>• Decreased white blood cell counts</li> <li>• Decreased blood levels of calcium</li> <li>• Hair loss</li> </ul> | <ul style="list-style-type: none"> <li>• Decreased red blood cell counts</li> <li>• Constipation</li> <li>• Dry eye</li> <li>• Vomiting</li> <li>• Increased blood levels of liver enzymes</li> </ul> | <ul style="list-style-type: none"> <li>• An eye problem called keratitis. See "What is the most important information I should know about DATROWAY?"</li> <li>• Increased blood levels of alkaline phosphatase</li> </ul> |
|--|---|---|

Please see the complete [Important Safety Information](#) on pages 18-19, the full [Prescribing Information](#), including **WARNINGS AND PRECAUTIONS**, and [Medication Guide](#).

**DATROWAY**<sup>®</sup>  
 datopotamab deruxtecan-dlnk  
 20 mg/mL INJECTION FOR INTRAVENOUS USE


# Response to treatment with DATROWAY and chemotherapy

The trial measured the overall response rate (tumor shrinking) results, which is the percentage of people who had a partial or complete response to therapy. A complete response means the tumor could not be seen on imaging tests. A partial response means the tumor shrank by at least 30%.



**36%** of people had their tumors shrink with DATROWAY

36% of people had a partial response and about 0.5% had a complete response.



**23%** of people had their tumors shrink with chemotherapy

23% of people had a partial response and 0% had a complete response.

Median duration of response (mDOR) is the length of time half of the people who responded to DATROWAY (partial or complete) continued to respond after the first response was seen. mDOR was about 6½ months with DATROWAY. mDOR was about 5½ months with chemotherapy.

## IMPORTANT SAFETY INFORMATION (CONT'D)

### What are the possible side effects of DATROWAY? (cont'd)

DATROWAY may cause fertility problems in males and females, which may affect your ability to have children. Talk to your healthcare provider if you have concerns about fertility.

Please see the complete [Important Safety Information](#) on pages 18-19, the full [Prescribing Information](#), including **WARNINGS AND PRECAUTIONS**, and [Medication Guide](#).

**DATROWAY**<sup>®</sup>  
datopotamab deruxtecan-dlnk  
20 mg/mL INJECTION FOR INTRAVENOUS USE

# DATROWAY can cause serious side effects

## LUNG PROBLEMS

Lung problems that may be severe, life-threatening, or lead to death can occur with DATROWAY. If you develop lung problems, your doctor may treat you with corticosteroid medicines. Tell your care team right away if you have any of the following: cough, trouble breathing or shortness of breath, fever, or other new or worsening breathing symptoms such as chest tightness or wheezing.

## EYE PROBLEMS

Eye problems are common with DATROWAY and can also be severe. Tell your care team right away if you develop any new or worsening eye problems during treatment with DATROWAY, including dry eyes, eye pain, eye redness, eye swelling, eye irritation, increased tears, feeling like something is in your eyes, discharge from your eyes, eye crusting, sensitivity to light, blurred vision, or vision changes.

## MOUTH ULCERS AND SORES

Mouth ulcers and sores are common with DATROWAY and can also be severe. Tell your care team right away if you develop mouth pain, swelling, redness, ulcers, or sores during treatment with DATROWAY.

## HARM TO YOUR UNBORN BABY

DATROWAY may cause harm to your unborn baby. Tell your care team right away if you become pregnant or think you might be pregnant during treatment with DATROWAY.

- If you are able to become pregnant, your care team should do a pregnancy test before you start treatment
- **Females** who are able to become pregnant should use effective birth control (contraception) during treatment and for 7 months after the last dose
- **Males** who have partners who are able to become pregnant should use effective birth control (contraception) during treatment and for 4 months after the last dose

*Please see pages 14-15 for important information on managing side effects.*


This is not a complete list of symptoms for DATROWAY-associated side effects or all possible side effects of DATROWAY. Call your doctor for medical advice about symptoms or side effects. You may report side effects to Daiichi Sankyo at 1-877-437-7763 or to FDA at 1-800-FDA-1088.

Please see the complete [Important Safety Information](#) on pages 18-19, the full [Prescribing Information](#), including **WARNINGS AND PRECAUTIONS**, and [Medication Guide](#).

**DATROWAY**<sup>®</sup>  
datopotamab deruxtecan-dlnk  
20 mg/mL INJECTION FOR INTRAVENOUS USE

# Common side effects seen with DATROWAY

In the trial, the majority of common side effects seen with DATROWAY were mild or moderate in severity.



**3.1% of people receiving DATROWAY discontinued treatment due to side effects**

- **Mild side effects** may not affect your daily activities, and medical intervention may not be needed
- **Moderate side effects** may affect your daily activities and may require some medical intervention
- **Severe side effects** usually require medical intervention and may have serious or life-threatening consequences

Please see the complete [Important Safety Information](#) on pages 18-19, the full [Prescribing Information](#), including **WARNINGS AND PRECAUTIONS**, and [Medication Guide](#).

# Select side effects that may require treatment

Side effects or changes in the way you receive DATROWAY are possible, but following specific guidance may help you care for certain ones. Your healthcare provider will check you for these side effects during your treatment with DATROWAY. Your healthcare provider may reduce your dose, delay treatment, or completely stop treatment with DATROWAY if you have certain side effects.



## LUNG PROBLEMS

**Lung problems that may be severe, life-threatening, or lead to death may occur while taking DATROWAY.** If you develop lung problems, your doctor may treat you with corticosteroid medicines. Tell your care team right away if you get any of the following:

- Cough
- Trouble breathing or shortness of breath
- Fever
- Other new or worsening symptoms such as chest tightness or wheezing



## EYE PROBLEMS

**Eye problems are common with DATROWAY and can also be severe.** Tell your care team right away if you develop any new or worsening eye problems including dry eyes, eye pain, eye redness, eye swelling, eye irritation, increased tears, feeling like something is in your eyes, discharge from your eyes, eye crusting, sensitivity to light, blurred vision, or vision changes. While on DATROWAY, there is certain guidance you should follow:

- You should use preservative-free lubricating eye drops at least 4 times a day and as needed
- Do not wear contact lenses during treatment with DATROWAY unless your eye specialist tells you to
- Your doctor will send you to an eye specialist to check your eyes when you start your treatment with DATROWAY, every year during treatment, at the end of treatment, and as needed for any new or worsening signs and symptoms of eye problems



**Remember to immediately report any and all side effects to your care team.**

## Select side effects that may require treatment (cont'd)



### MOUTH ULCERS AND SORES

Mouth ulcers and sores are common with DATROWAY and can also be severe. Tell your healthcare provider right away if you develop mouth pain, swelling, redness, ulcers, or sores during treatment with DATROWAY. To help care for them, your doctor will prescribe a steroid-containing mouthwash to use 4 times a day and as needed during treatment. Keep in mind:

- Work with your care team to make a mouthwash routine that you may follow and use as instructed
- Holding ice chips or ice water in your mouth during your DATROWAY infusions may help with mouth sores



### NAUSEA AND VOMITING

Nausea and vomiting are possible, but this may help prevent them:

- Take anti-nausea medicine prescribed by your doctor before treatment and as needed after treatment



For more information on addressing side effects, visit [DATROWAY.com](https://www.DATROWAY.com)

# DATROWAY4U: Treatment support

DATROWAY4U has programs that may help you access and afford your prescribed DATROWAY treatment, including benefit reviews, prior authorizations, claims appeals, and paying for your prescription.



DATROWAY4U may help you understand your insurance coverage. Knowing this information may simplify the process of getting your prescription.



The DATROWAY Patient Savings Program may help you with out-of-pocket costs if you are commercially insured. There are no income requirements to participate.



DATROWAY4U is designed to help insured, uninsured, and underinsured people access treatment.

**DATROWAY**<sup>®</sup> 4U  
datopotamab deruxtecan-dlnk  
20 mg/mL INJECTION FOR INTRAVENOUS USE



Visit [DATROWAY4U.com](https://www.DATROWAY4U.com) or call  
**1-855-DATRO4U** (1-855-328-7648)  
to learn more

Please see the complete [Important Safety Information](#) on pages 18-19, the full [Prescribing Information](#), including **WARNINGS AND PRECAUTIONS**, and [Medication Guide](#).

**DATROWAY**<sup>®</sup>  
datopotamab deruxtecan-dlnk  
20 mg/mL INJECTION FOR INTRAVENOUS USE

# Support from the community

Navigating breast cancer and finding support can be a challenge, but there are resources available to help you get the support you deserve.



## CANCER.ORG

The **American Cancer Society** is an organization aimed to improve the lives of people with cancer and their families through advocacy, research, and patient support, to ensure everyone has an opportunity to prevent, detect, treat, and survive cancer.



LIVING BEYOND  
BREAST CANCER®

## LBBC.ORG

**Living Beyond Breast Cancer** is a national nonprofit that connects people with trusted breast cancer information and a community of support.



## SHARECANCERSUPPORT.ORG

**SHARE Cancer Support** is a national nonprofit that supports and educates anyone who has been diagnosed with breast or gynecologic cancer and provides critical information to the general public about signs, symptoms, diagnosis, and treatment options.



## METAVIVOR.ORG

**METAvivor** is an organization that focuses exclusively on stage IV metastatic breast cancer. Their mission is to improve the lives of people living with metastatic breast cancer by funding research, advancing federal policies through advocacy, and facilitating a community of peer-to-peer support.



## KOMEN.ORG

**Susan G. Komen's** mission is to save lives by meeting the most critical needs in our communities and investing in breakthrough research to prevent and cure breast cancer.

This is not an all-inclusive list of resources.

Please see the complete [Important Safety Information](#) on pages 18-19, the full [Prescribing Information](#), including **WARNINGS AND PRECAUTIONS**, and [Medication Guide](#).

**DATROWAY**®  
datopotamab deruxtecan-dlnk  
20 mg/mL INJECTION FOR INTRAVENOUS USE

# INDICATION AND IMPORTANT SAFETY INFORMATION

## What is DATROWAY®?

DATROWAY is a prescription medicine used to treat adults who have:

- hormone receptor (HR)-positive and human epidermal growth factor receptor 2 (HER2)-negative breast cancer:
  - that cannot be removed by surgery (unresectable) or has spread to other parts of the body (metastatic), **and**
  - who have received prior endocrine-based therapy and chemotherapy treatment for unresectable or metastatic disease.

It is not known if DATROWAY is safe and effective in children.

## What is the most important information I should know about DATROWAY?

### DATROWAY can cause serious side effects, including:

- **Lung problems that may be severe, life-threatening, or that may lead to death.** If you develop lung problems, your healthcare provider may treat you with corticosteroid medicines. Tell your healthcare provider right away if you get any of the following signs and symptoms:
  - cough
  - trouble breathing or shortness of breath
  - fever
  - other new or worsening breathing symptoms such as chest tightness or wheezing
- **Eye problems.** Eye problems are common with DATROWAY and can also be severe. Tell your healthcare provider right away if you develop any new or worsening eye problems during treatment with DATROWAY, including dry eyes, eye pain, eye redness, eye swelling, eye irritation, increased tears, feeling like something is in your eyes, discharge from your eyes, eye crusting, sensitivity to light, blurred vision or vision changes.
  - You should use preservative-free lubricating eye drops at least 4 times a day and as needed.
  - Do not wear contact lenses during treatment with DATROWAY unless your eye specialist tells you to.
  - Your healthcare provider will send you to an eye specialist to check your eyes when you start your treatment with DATROWAY, every year during treatment, at the end of treatment, and as needed for any new or worsening signs and symptoms of eye problems.
- **Mouth ulcers and sores.** Mouth ulcers and sores are common with DATROWAY and can also be severe. Tell your healthcare provider right away if you develop mouth pain, swelling, redness, ulcers, or sores during treatment with DATROWAY.
  - Your healthcare provider will prescribe a steroid-containing mouthwash to use 4 times a day and as needed during treatment with DATROWAY.
  - You should hold ice chips or ice water in your mouth during your DATROWAY infusions.

**Your healthcare provider will check you for these side effects during your treatment with DATROWAY. Your healthcare provider may reduce your dose, delay treatment, or completely stop treatment with DATROWAY if you have severe side effects.**

- **Harm to your unborn baby.** Tell your healthcare provider right away if you become pregnant or think you might be pregnant during treatment with DATROWAY.
  - If you are able to become pregnant, your healthcare provider should do a pregnancy test before you start treatment with DATROWAY.
  - **Females** who are able to become pregnant should use effective birth control (contraception) during treatment with DATROWAY and for 7 months after the last dose.
  - **Males** who have female partners that are able to become pregnant should use effective birth control (contraception) during treatment with DATROWAY and for 4 months after the last dose. See **“What are the possible side effects of DATROWAY?”** for more information about side effects.

Please see accompanying full [Prescribing Information](#), including **WARNINGS AND PRECAUTIONS**, and [Medication Guide](#).

**DATROWAY**<sup>®</sup>  
datopotamab deruxtecan-dlnk  
20 mg/mL INJECTION FOR INTRAVENOUS USE

# INDICATION AND IMPORTANT SAFETY INFORMATION (CONT'D)

**Before receiving DATROWAY, tell your healthcare provider about all of your medical conditions, including if you:**

- Have lung or breathing problems.
- Have eye problems.
- Use contact lenses.
- Are breastfeeding or plan to breastfeed. It is not known if DATROWAY passes into your breast milk. Do not breastfeed during treatment with DATROWAY and for 1 month after the last dose.

**Tell your healthcare provider about all the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements.**

**How will I receive DATROWAY?**

- You will receive DATROWAY into your vein through an intravenous (IV) line by your healthcare provider.
- DATROWAY is usually given 1 time every three weeks (21-day treatment cycle).
- You will receive your first infusion over 90 minutes. If you do not have problems with your first infusion, you may receive your next infusions over 30 minutes.
- You will be monitored for side effects for at least 1 hour after your first 2 infusions. If you do not have problems after your second infusion, you will be monitored for at least 30 minutes after each following infusion.
- Your healthcare provider will decide how many treatments you need.
- Your healthcare provider will give you medicines before your infusion to help prevent nausea, vomiting, and infusion-related reactions.
- Your healthcare provider may slow down or temporarily stop your infusion of DATROWAY if you have an infusion-related reaction, or permanently stop DATROWAY if you have severe infusion reactions.
- If you miss a planned dose of DATROWAY, call your healthcare provider right away to schedule an appointment. Do not wait until the next planned treatment cycle.

**What are the possible side effects of DATROWAY?**

**DATROWAY can cause serious side effects, including:**

- See “What is the most important information I should know about DATROWAY?”

**The most common side effects of DATROWAY when used in adults with HR-positive HER2-negative breast cancer include:**

- Nausea
- Tiredness
- Decreased white blood cell counts
- Decreased blood levels of calcium
- Hair loss
- Decreased red blood cell counts
- Constipation
- Dry eye
- Vomiting
- Increased blood levels of liver enzymes
- An eye problem called keratitis. See “What is the most important information I should know about DATROWAY?”
- Increased blood levels of alkaline phosphatase

DATROWAY may cause fertility problems in males and females, which may affect your ability to have children. Talk to your healthcare provider if you have concerns about fertility.

**These are not all of the possible side effects of DATROWAY. Call your healthcare provider for medical advice about side effects. You may report side effects to Daiichi Sankyo at 1-877-437-7763 or to FDA at 1-800-FDA-1088.**

Please see accompanying full [Prescribing Information](#), including **WARNINGS AND PRECAUTIONS**, and [Medication Guide](#).

**DATROWAY**<sup>®</sup>  
datopotamab deruxtecan-dlnk  
20 mg/mL INJECTION FOR INTRAVENOUS USE

# Key reminders about treatment with DATROWAY



DATROWAY is given through an IV infusion **once every 3 weeks** and takes **90 minutes** to administer your first dose. If you do not have any infusion-related reactions during your first treatment, your infusions could be as short as **30 minutes**.



DATROWAY4U is available to help you **access and afford your prescribed DATROWAY treatment**.\*

\*Eligibility required.



**Stay informed about your treatment.** Visit **DATROWAY.com** to learn more about DATROWAY and explore resources available for you and your family.

## What is DATROWAY®?

DATROWAY is a prescription medicine used to treat adults who have:

- hormone receptor (HR)-positive and human epidermal growth factor receptor 2 (HER2)-negative breast cancer:
  - that cannot be removed by surgery (unresectable) or has spread to other parts of the body (metastatic), **and**
  - who have received prior endocrine-based therapy and chemotherapy treatment for unresectable or metastatic disease.

It is not known if DATROWAY is safe and effective in children.

## What is the most important information I should know about DATROWAY?

**DATROWAY can cause serious side effects, including:**

- **Lung problems that may be severe, life-threatening, or that may lead to death.** If you develop lung problems, your healthcare provider may treat you with corticosteroid medicines. Tell your healthcare provider right away if you get any of the following signs and symptoms:
  - cough
  - trouble breathing or shortness of breath
  - fever
  - other new or worsening breathing symptoms such as chest tightness or wheezing

Please see the complete [Important Safety Information](#) on pages 18-19, the full [Prescribing Information](#), including **WARNINGS AND PRECAUTIONS**, and [Medication Guide](#).



DATROWAY® is a registered trademark of Daiichi Sankyo Company, Limited.

© 2025 Daiichi Sankyo, Inc. and AstraZeneca. PP-US-DTB-0493 | US-104407 Last Updated 09/25

**DATROWAY**®  
datopotamab deruxtecan-dlnk  
20 mg/mL INJECTION FOR INTRAVENOUS USE